Publicaciones en colaboración con investigadores/as de St George's, University of London (21)

2024

  1. New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 10, Núm. 3, pp. 219-244

2023

  1. EHRA expert consensus document on the management of arrhythmias in frailty syndrome, endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA)

    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, Vol. 25, Núm. 4, pp. 1249-1276

  2. New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 9, Núm. 4, pp. 353-370

  3. Triglycerides revisited: is hypertriglyceridaemia a necessary therapeutic target in cardiovascular disease?

    European heart journal. Cardiovascular pharmacotherapy, Vol. 9, Núm. 6, pp. 570-582

2022

  1. Challenges in cardiovascular pharmacogenomics implementation: a viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy

    European heart journal. Cardiovascular pharmacotherapy, Vol. 8, Núm. 1, pp. 100-103

  2. Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy

    European heart journal. Cardiovascular pharmacotherapy, Vol. 8, Núm. 4, pp. 406-419

  3. Racial and ethnic differences in pharmacotherapy to prevent coronary artery disease and thrombotic events

    European heart journal. Cardiovascular pharmacotherapy, Vol. 8, Núm. 7, pp. 738-751

  4. Subgroup analyses in randomized clinical trials: value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 8, Núm. 3, pp. 302-310

  5. The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy

    European heart journal. Cardiovascular pharmacotherapy, Vol. 8, Núm. 1, pp. 85-99

2021

  1. Results of an international crowdsourcing survey on the treatment of non-ST segment elevation ACS patients at high-bleeding risk undergoing percutaneous intervention

    International Journal of Cardiology, Vol. 337, pp. 1-8

  2. The age of randomized clinical trials: Three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trials

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 7, Núm. 5, pp. 453-459

  3. Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease: A review in collaboration with the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 7, Núm. 6, pp. 557-567

2020

  1. Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: Systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 6, Núm. 2, pp. 86-93

  2. Cardiovascular pharmacotherapy in older people: Challenges posed by cardiovascular drug prescription in the elderly

    European Heart Journal - Cardiovascular Pharmacotherapy

2019

  1. Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: A current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 5, Núm. 3, pp. 171-180

2018

  1. Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy

    European Heart Journal, Vol. 39, Núm. 24, pp. 2274-2281

2017

  1. Comprehensive efforts to increase adherence to statin therapy

    European Heart Journal, Vol. 38, Núm. 32, pp. 2473-2477

2016

  1. Management of stable angina: A commentary on the European Society of Cardiology guidelines

    European Journal of Preventive Cardiology, Vol. 23, Núm. 13, pp. 1401-1412

2015

  1. Gender differences in the effect of cardiovascular drugs: A position document of theworkinggroup on pharmacology and drug therapy of the ESC

    European Heart Journal

  2. Unresolved issues in the management of chronic stable angina

    International Journal of Cardiology, Vol. 201, pp. 200-207